Alterity Therapeutics CEO to Speak at Virtual BTIG Biotechnology Conference 2026 on July 28-29

Alterity Therapeutics’ Commitment to Neurodegenerative Disease Innovation

Alterity Therapeutics is a clinical-stage biotech company dedicated to developing disease-modifying therapies for neurodegenerative conditions, with a primary focus on Multiple System Atrophy (MSA) and related Parkinsonian disorders. These diseases represent significant unmet medical needs with limited treatment options. Headquartered in Melbourne, Australia, and San Francisco, California, Alterity operates within two key biotech hubs, facilitating access to both Australian regulatory pathways and the expansive U.S. pharmaceutical market.

The company’s strategy combines advanced clinical development with a broad drug discovery platform aimed at generating patentable chemical compounds that target neurological disease pathology. This dual approach enables Alterity to build a robust pipeline of potential therapies while advancing its lead candidate through late-stage clinical trials. Alterity is publicly traded on the Australian Securities Exchange (ASX) and NASDAQ, underscoring its international investor reach.

Clinical Success of ATH434 and Phase 3 Development Plans

ATH434 is Alterity’s lead clinical asset and most advanced program. It has demonstrated clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 trial involving participants with Multiple System Atrophy. These pivotal Phase 2 results provide the foundation for progressing to larger, late-stage testing. Additionally, positive data from an open-label Phase 2 trial in advanced MSA patients indicate consistent therapeutic benefits across diverse patient groups.

Moving ATH434 into Phase 3 marks a critical milestone for Alterity. Phase 3 pivotal trials are designed to confirm efficacy and safety across broader patient populations and form the primary basis for regulatory approval submissions. The company is actively preparing to launch this Phase 3 trial, which could position ATH434 as a potential first-in-class or best-in-class treatment for MSA—a rare, rapidly progressing neurodegenerative disorder with high unmet needs.

BTIG Biotechnology Conference 2026: A Platform for Investor Engagement

Alterity’s participation in the virtual BTIG Biotechnology Conference 2026 on 28–29 July offers a strategic opportunity to engage with U.S.-based institutional investors. CEO Dr. David Stamler will conduct one-on-one meetings, reflecting the company’s commitment to transparent communication during this pivotal development phase. The BTIG conference is a well-regarded event attracting institutional investors, analysts, and fund managers focused on emerging biotech innovations.

Announced on 21 July 2026, this engagement allows Alterity to update investors on recent progress and upcoming milestones. These personalized meetings facilitate in-depth discussions on clinical strategy, the rationale for advancing ATH434 to Phase 3, and the market potential for MSA and related disorders. Such direct investor interaction is crucial for clinical-stage biotech firms, enabling management to address detailed questions about trial design, regulatory pathways, and timelines that influence investment decisions.

Multiple System Atrophy: Disease Overview and Market Potential

Multiple System Atrophy is a rare, rapidly progressive neurodegenerative disease characterized by alpha-synuclein protein accumulation in the brain. Affecting multiple bodily systems, MSA presents symptoms including parkinsonism, cerebellar dysfunction, and autonomic failure. Classified as a rare disease globally, MSA offers regulatory incentives such as orphan drug designation, which grants market exclusivity upon approval.

Currently, no disease-modifying therapies exist for MSA, with treatments focusing on symptom management rather than slowing progression. ATH434 aims to fill this gap by potentially preserving neurological function and quality of life in early to intermediate stage patients. The commercial opportunity for an effective MSA therapy is significant within this niche, with potential expansion into related Parkinsonian disorders broadening the addressable market.

Regulatory and Clinical Development Pathway for ATH434

ATH434’s progression from Phase 2 to Phase 3 aligns with regulatory standards set by agencies such as the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA). Phase 2 trials, involving 100–300 subjects, assess preliminary efficacy and safety. Positive Phase 2 outcomes support advancement to larger Phase 3 trials designed to generate robust data for regulatory approval.

The upcoming Phase 3 trial will be more extensive and complex, requiring meticulous design to meet regulatory expectations. Alterity’s drug discovery platform supports potential follow-on candidates should ATH434 face development challenges. Regulatory provisions like orphan drug, breakthrough therapy designations, and accelerated approval pathways may facilitate faster review if eligibility criteria are met.

Dual Listing and Investor Access Strategy

Alterity’s listings on the Australian Securities Exchange (ASX:ATH) and NASDAQ (ATHE) reflect its strategy to attract capital from both Australian and U.S. markets. The ASX listing engages Australian investors, while NASDAQ provides access to the world’s largest biotech equity market. This dual listing approach maximizes capital availability and broadens investor reach.

Hosting investor meetings at the U.S.-based BTIG Biotechnology Conference highlights the importance of the U.S. investor base. The U.S. pharmaceutical market is the largest globally, and U.S. institutional investors bring extensive expertise in evaluating biotech clinical programs. Active engagement with these investors supports visibility and capital acquisition critical for late-stage clinical development.

Intellectual Property and Patent Strategy

Alterity emphasizes its broad drug discovery platform that produces patentable chemical compounds targeting neurological disease mechanisms. Patent protection is vital for securing market exclusivity and recovering R&D investments. The company’s strategy focuses on building a diversified intellectual property portfolio beyond ATH434 to sustain competitive advantages.

Regulatory filings acknowledge risks related to intellectual property, including challenges in obtaining and enforcing patents and ensuring freedom to operate. Successful patent prosecution and enforcement for ATH434 and future candidates are essential for extending commercial potential and protecting innovation.

Risks in Clinical-Stage Biotechnology Development

As a clinical-stage biotech company, Alterity faces typical risks such as financing difficulties, development delays, regulatory hurdles, production challenges, and market uncertainties. Phase 3 trial outcomes may differ from Phase 2 results, potentially impacting efficacy and safety profiles. Unexpected adverse effects or insufficient therapeutic benefit could impede product approval.

Regulatory approval is not guaranteed; even with successful Phase 3 results, agencies may impose restrictions or limit indications. Access to additional funding is critical for late-stage trials and commercialization, depending on capital markets and investor confidence. These risks are material factors for investors considering biotechnology opportunities.

Leadership and Communication Strategy

Dr. David Stamler, CEO of Alterity Therapeutics, authorized the announcement regarding BTIG conference participation. Executive involvement in investor conferences and one-on-one meetings is standard practice, especially approaching key development milestones. Dr. Stamler’s medical background (M.D.) supports informed strategic decisions on clinical development.

Investor relations are managed by Elyse Shapiro and Remy Bernarda, while media communications are handled by external advisors NWR Communications and Tiberend Strategic Advisors. This structured communication framework ensures effective dissemination of company updates to investors and media covering biotech and pharmaceutical sectors.